Opioid Potency and Clinical Applications

Potency and Dosing Considerations

Hydromorphone is approximately 5-10 times more potent than morphine when used in equianalgesic doses, requiring careful dose conversion when switching between these opioids, according to the British Journal of Cancer 1
When converting from oral morphine to subcutaneous morphine, the dose should be divided by three to achieve roughly equianalgesic effect, as recommended by the British Journal of Cancer 2

Hydromorphone has better solubility than morphine, making it preferred for parenteral administration when smaller volume injections are necessary, as noted by the British Journal of Cancer 2

Both morphine and hydromorphone are effective for moderate to severe cancer pain, with morphine being the first-line opioid of choice, according to the Annals of Oncology 3
Hydromorphone is an effective alternative to oral morphine when patients develop intolerable adverse effects with morphine before achieving adequate pain relief, as reported by the British Journal of Cancer 1 and 4
In opioid-naïve patients, starting doses should be lower: oral morphine 10-12 mg/day divided into 5-6 doses for elderly patients, or hydromorphone at equivalent reduced doses, as recommended by the Annals of Oncology 5

The average relative potency ratio of oral to intravenous morphine is between 1:2 and 1:3, similar to the ratio for hydromorphone, according to the Annals of Oncology 3
Both medications are available in immediate-release and modified-release formulations for oral administration, as noted by the British Journal of Cancer 1
For breakthrough pain, rescue doses are typically 10% of the total daily dose for both medications, as recommended by the Annals of Oncology 6

Fentanyl and buprenorphine are safer than both morphine and hydromorphone in patients with chronic kidney disease stages 4 or 5, according to the Annals of Oncology 3

Both medications have similar adverse effect profiles when used at equianalgesic doses, including constipation, nausea, sedation, and respiratory depression, as reported by the British Journal of Cancer 1
Opioid rotation from morphine to hydromorphone (or vice versa) may be beneficial when patients develop intolerable side effects, particularly CNS toxicity, as noted by the British Journal of Cancer 4

For opioid-naïve patients with moderate pain, start with low doses: oral morphine 12 mg/day divided in 5-6 doses or equivalent hydromorphone, as recommended by the Annals of Oncology 5
Both medications should be prescribed with a rescue dose for breakthrough pain, typically 10-30% of the 4-hourly dose, as recommended by the British Journal of Cancer 1 and the Annals of Oncology 6